Riddhi Siddhi Gluco Biols share price today

Riddhi Siddhi Gluco Biols Ltd's share price was ₹690.00 at the close on 30 October 2026. It has been rising for 25 weeks. That is 2.7% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 1 week in a row.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Riddhi Siddhi Gluco Biols Ltd is in stage 2. The phase helps read everything below.

In the last 52 weeks it traded between ₹411 and ₹823, and at that close it sat 68% of the way up from that low.

Over the last 11 years the share price moved +128% while the NIFTY 500 moved +231%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

One change stood out: revenue down on a year earlier for 4 quarters in a row.

1. Revenue down on a year earlier for 4 quarters in a row

   In the June 2026 quarter revenue was ₹90 crore, -41.9% on a year earlier.

For April to June 2026 (the quarter ended 30 June 2026), Riddhi Siddhi Gluco Biols reported revenue of ₹89.9 crore, down 41.9% from ₹155 crore a year earlier, and a profit of ₹3.01 crore, down 62.6% from ₹8.04 crore.

Riddhi Siddhi Gluco Biols results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Riddhi Siddhi Gluco Biols closed at ₹690.00 on 30 October 2026, up 26.8% from ₹544.00 a year earlier (31 October 2025) and up 91.1% over five years. Its highest weekly close since May 2016 was ₹840.30 on 23 February 2018.

Riddhi Siddhi Gluco Biols share price: then and now

Weekly closing prices. Each change is the move from that price to the 30 Oct 2026 close. A day's intraday high or low can go beyond these weekly closes.

553 weekly closes from 13 May 2016 to 30 October 2026.

30 Oct 2026: Riddhi Siddhi Gluco Biols closed at ₹690.00, up 7.8% on the week and down 2.9% on the month. Results for April to June 2026: Revenue down 41.9% and profit down 62.6% on a year earlier.

Not in its latest year. Riddhi Siddhi Gluco Biols Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 4 of its last 11 reported years, so there is a history but no current dividend (as of 30 October 2026).

Riddhi Siddhi Gluco Biols is not on any of our India lists this week.

Riddhi Siddhi Gluco Biols Ltd earned ₹3.0 Cr of net profit in the Jun 2026 quarter, −62.6% on the same quarter a year earlier. The full FY26 year was a loss of ₹12.0 Cr. That is 3.3% of the quarter's revenue. The same quarter a year earlier earned ₹8.0 Cr. 3 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Why profit moved: revenue changed −41.9% on a year earlier and the margin moved −2.8 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −288.9% and revenue −38.4%. Profit is growing slower than sales: rising costs are taking part of the growth.

Riddhi Siddhi Gluco Biols Ltd reported ₹89.9 Cr of revenue in the Jun 2026 quarter, −41.9% on the same quarter a year earlier. Over 10 years it has grown −3.6% a year on average. The last full year, FY26, came in at ₹236 Cr. The last four reported quarters add to ₹171 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹236 Cr, +73.5% on the year before.

Recent pace: the last four quarters grew −38.4% on average, against −3.6% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −38.0%, against −11.5% a year over the last 8 quarters (rolling over).

Riddhi Siddhi Gluco Biols Ltd's operating margin was −3.0% in the Jun 2026 quarter, 2.8 percentage points lower than the same quarter a year ago. Across 11 years it has been between −9.0% and 13.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −2.8 percentage points on the year while gross margin changed +1.4 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 409% of Riddhi Siddhi Gluco Biols Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 its operations used ₹9.0 Cr of cash, against −₹12.0 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹0.0 Cr of spending on assets, free cash was −₹9.0 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 409% of profit came in as cash: the cash cycle got 145 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 2.2× depreciation over three years. The next section checks what that spending is building.

Riddhi Siddhi Gluco Biols Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 66 days in FY26, down from 211 days in FY21. It spent ₹62.0 Cr on assets over the last 3 years. Customers take 13 days to pay, and stock sits for 79 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹236 Cr, each day of that cycle ties up about ₹0.6 Cr, so roughly ₹43.0 Cr is tied up in the business at any time.

FY26: customers took 13 days to pay and stock sat for 79 days, about 2.6 months of sales sitting as stock, for a full cycle of 66 days, shorter than FY21's 211.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 79 days. Customers pay about 13 days after that. Suppliers are paid at 26 days. Together that makes the 66-day cycle.

Spending on assets: ₹62.0 Cr over the last 3 years, against ₹28.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Riddhi Siddhi Gluco Biols Ltd's P/E is 34.8×, about the highest it has ever been. Its usual P/E (the middle reading) is 8.5×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.